Inhibition of DNA binding of the NF-Y transcription factor by the pyrrolobenzodiazepine-polyamide conjugate GWL-78

Minal Kotecha,1 Jerome Kluza,1 Geoff Wells,2 C. Caroline O’Hare,1 Claudia Forni,3 Roberto Mantovani,3 Philip W. Howard,2 Peter Morris,1 David E. Thurston,2 John A. Hartley,1 and Daniel Hochhauser1

1Cancer Research UK Drug-DNA Interactions Research Group, UCL Cancer Institute, University College London; 2Cancer Research UK Gene Targeted Drug Design Research Group, School of Pharmacy, University of London, London, United Kingdom; and 3Dipartimento di Scienze Biomolecolari e Biotecnologie, Universita degli Studi di Milano, Milan, Italy

Abstract
Many genes involved in cell cycle control have promoters that bind the heterotrimERIC transcription factor NF-Y. Several minor-groove binding drugs have been shown to block interactions of transcription factors with cognate DNA-binding sequences. We showed previously that noncovalent minor-groove binding agents block interactions of NF-Y with the promoter of topoisomerase IIα (topo IIα). In this study, we investigated the ability of GWL-78, a pyrrolobenzodiazepine-poly(N-methylpyrrole) conjugate, to inhibit the binding of NF-Y to DNA. Electrophoretic mobility shift assays showed that GWL-78 could displace NF-Y bound to several CCAAT motifs within promoters of genes involved in cell cycle progression. DNase I footprinting of the topo IIα promoter confirmed binding of GWL-78 to AT-rich sequences corresponding to the preferred binding site of NF-Y. Incubation with GWL-78 resulted in displacement of NF-Y binding to DNA. Chromatin immunoprecipitation assays on the topo IIα promoter showed that GWL-78 was able to enter the nucleus and interact with specific DNA sequences. Treatment of NIH3T3 cells with GWL-78 resulted in a block of cell cycle progression, which did not involve activation of p53. Thus, agents such as GWL-78 may be useful in modulating transcription and blocking cellular proliferation.

Introduction
DNA-interactive drugs are widely used in the treatment of human cancers. There is considerable evidence of preferred DNA sequences to which several of these agents bind. For example, doxorubicin has been shown to bind preferentially to 5′-TTTTG-Pu-3′ sequences (3). Also, we have shown previously that the bis-benzimidazole Hoechst 33342 binds to inverted CCAAT sequences within the topo IIα promoter and thereby blocks binding of the heterotrimERIC transcription factor NF-Y (4). NF-Y is a ubiquitously expressed CCAAT-binding protein with roles in cell differentiation and cell cycle progression (5–7). NF-Y cooperates with other transcription factors and regulates promoter activity. It is composed of three subunits, A, B, and C. Both B and C subunits are able to interact with histones, and both A and C subunits are able to bind proteins (8, 9). Abrogation of NF-Y function by expression of a dominant-negative gene results in loss of cell cycle progression (7).

More recently, connections between NF-Y and the p53 pathway were characterized in cells with wild-type p53 and in cells with tumour-derived mutants (10, 11). Importantly, in the latter case, gain-of-function p53 mutants were shown to stimulate growth through binding to the CCAAT/NF-Y complex. Therefore, targeting NF-Y interactions with DNA could be a potential strategy for blocking proliferation of cancer cells. To obtain inhibitors of NF-Y binding to DNA with improved efficacy and potency, we developed a novel series of pyrrolobenzodiazepine (PBD) conjugates, including the molecule GWL-78 (Fig. 1; ref. 18). The PBD series were developed as minor-groove binding covalent molecules. PBDs are antitumor antibiotics derived from Streptomyces species and include anthramycin and tomatamycin (12, 13). PBDs interact within the minor groove of DNA by binding covalently to the C2-amino
position of a guanine residue. For example, the pyrrolo[2,1-c][1,4]benzodiazepine dimer SJG-136 (NSC 694501) selectively cross-links guanine residues located on opposite strands of DNA and exhibits potent in vitro cytotoxicity (12). It spans six nucleotides with a preference for binding to purine-GATC-pyrimidine sequences (14).

The effects of GWL-78 on the binding of NF-Y to DNA were determined using an electrophoretic mobility shift assay (EMSA) on sequences derived from several promoters regulated by NF-Y. The ability of GWL-78 to inhibit NF-Y binding was investigated in cells using a chromatin immunoprecipitation (ChIP) assay. DNase I footprinting was carried out. These results suggest that PBDs can modulate gene expression by inhibiting specific protein/DNA interactions.

**Materials and Methods**

**Cell Lines and Culture Conditions**

NIH3T3 cells (obtained from Cancer Research UK London Research Institute) were grown in DMEM (Auto-gen Bioclear) supplemented with 10% newborn calf serum and 1% glutamine and incubated at 37°C in 5% CO₂. CaCo2 cells were also obtained from Cancer Research UK London Research Institute and grown in RPMI (Bioclear) supplemented with 10% FCS and 1% glutamine and incubated at 37°C in 5% CO₂.

**Serum Starvation and Cell Cycle Synchronization**

NIH3T3 cells, 70% confluent, were washed three times with PBS and maintained in DMEM supplemented with 0.1% newborn calf serum for 82 h before replacing the culture medium with DMEM supplemented with 10% newborn calf serum and 0.4 mmol/L mimosine (Sigma) for 14 h. The cells were subsequently washed with PBS, released from synchronization, and allowed to progress through the cell cycle by adding complete medium.

**Preparation of Nuclear Extracts**

All steps of the preparation of nuclear extracts were done at 4°C in the presence of a protease inhibitor mix (Complete; Boehringer). Cells were rinsed with ice-cold PBS, scraped from the surface, and collected by centrifugation. The cells were washed with 5 volumes of hypotonic buffer containing 10 mmol/L K-HEPES (pH 7.9), 1.5 mmol/L MgCl₂, 10 mmol/L KCl, and 0.5 mmol/L DTT (Sigma). Subsequently, the cells were resuspended in 3 volumes of hypotonic buffer, incubated on ice for 10 min, and subjected to 20 strokes of a Dounce homogenizer and the nuclei collected by centrifugation. The nuclear pellet was resuspended in 0.5 volumes of low-salt buffer containing 20 mmol/L K-HEPES (pH 7.9), 0.2 mmol/L K-EDTA, 25% glycerol, 1.5 mmol/L MgCl₂, 20 mmol/L KCl, and 0.5 mmol/L DTT. While stirring, 0.5 volume of high-salt buffer (as low-salt buffer but containing 1.4 mol/L KCl) was added and the nuclei were extracted for 30 min. Subsequently, the mixture was centrifuged for 30 min at 14,000 rpm in an Eppendorf centrifuge and the supernatant was dialyzed in tubing with a 12-kDa cutoff (Sigma) for 1 h in a 100 times excess of dialysis buffer containing 20 mmol/L K-HEPES (pH 7.9), 0.2 mmol/L K-EDTA, 20% glycerol, 100 mmol/L KCl, and 0.5 mmol/L DTT. The dialyzed fraction was centrifuged for 30 min at 14,000 rpm in an Eppendorf centrifuge and the supernatant was snap frozen in an ethanol dry ice bath and stored at -80°C. The protein concentration of the nuclear extract was assayed using a Bio-Rad micro protein assay kit.

**Electrophoretic Mobility Shift Assay**

The oligonucleotides (MWG Biotech) containing inverted CCAAT boxes (ICB; italicized) used in the EMSA assay are topo IIa ICB1 sense 5’-CGAGTCAGGGATTTGCCAT-3’ and antisense 5’-GAAGCAGACCAGCCAATCTGGTACCTCG-3’, ICB2 sense 5’-GCGAAGTACAGGATTTGCCATTTGTTCTGGGACC-3’ and antisense 5’-CGTCCAGAGAACCATACTGGATCTGGCCC-3’, ICB3 sense 5’-CTCCCTAACTGGTTATATCCAAAC-3’ and antisense 5’-GTGGTAAATAAAAACCATCAGGTTAGGAGGAGCCCAATCTGGTACCTCG-3’, and ICB4 sense 5’-GAGCCCTTCTTCTATTGGCCAGATCTGCTTTCC-3’ and antisense 5’-ACCCCTAATTTCAGGGGGGAGAT-3’.

Oligonucleotides corresponding to mdr1 sense 5’-CGGACTGGCCTTCTATTGGCCAGATCTGCTTTCC-3’ and antisense 5’-TTCCCTGCCAGCAGCAATCAGGCTTACCA-3’, hOGG1 sense 5’-ACCCCTAATTTCAGGGGGGAGAT-3’ and antisense 5’-CCAGATTCCCTGCCCAGAGGTTAGGGAGGCGCCAATTACGGGTT-3’, cdc2/cdk1 sense 5’-CCGGTACGGCGCTATGTCGTCGGACC-3’ and antisense 5’-CTGTCGCCCATATCGGCGTCTATGTCGTCGGACC-3’, and cyclin B1 sense 5’-CTGTCGCCCATATCGGCGTCTATGTCGTCGGACC-3’ were also used for EMSA. Oligonucleotides of similar sequence containing mutated ICBs were used as specific competitors, the wild-type ICB sequence replaced by AAAAC or GTTT in sense and antisense oligonucleotides, respectively. Sense and antisense oligonucleotides were
an equal ratio. Double-stranded oligonucleotides were 5′-end labeled with T4 kinase (NEB) using [γ-32P]ATP and subsequently purified on Bio-Gel P-6 columns (Bio-Rad). EMSAs were performed as described (15) on 5 μg nuclear extract. For supershifts, antibodies against NF-Y-A (IgG fraction; Rocklands) were used and the preincubation on ice was extended for a total of 1.5 h. On addition of ~0.1 ng radiolabeled probe, the incubation was continued for 2 h at room temperature. In competition experiments, radiolabeled probe and competitor were added simultaneously. Subsequently, 0.5 μL loading buffer [25 mmol/L Tris-HCl (pH 7.5), 0.02% bromophenol blue, and 10% glycerol] was added and the samples were separated on a 4% polyacrylamide gel in 0.5× TBE containing 2.5% glycerol at 4°C. After drying the gels, the radioactive signal was visualized by exposure to Kodak X-Omat-LS film.

**NF-Y Activation Assay by ELISA**

GWL-78 (0.1-5 μmol/L) was added in a 96-well plate to which an oligonucleotide containing CCAAT box has been immobilized. Nuclear extract of HT-29 cells were added to each well and incubated for 1 h at room temperature. DNA binding of NF-Y was assessed by TransAM NF-Y Kit (Active Motif). Briefly, samples were incubated with a primary antibody specific to an epitope on the bound form of NF-Y and a horseradish peroxidase–conjugated IgG antibody providing a colorimetric reaction. Absorbance was read on a spectrophotometer at 450 nm with a reference of 655 nm.

**DNase I Footprinting**

A radiolabeled probe of 479 bp corresponding to positions -489 to -10 relative to the transcriptional start site of the top IIα promoter was generated. Antisense oligonucleotide 5′-GTCGGTTAGAGAGCTTCCACTTG-3′ (4 pmol) was 5′-end labeled with T4 kinase (Invitrogen) using [γ-32P]ATP in a 10 μL reaction followed by heat inactivation for 20 min at 65°C. Subsequently, 4 pmol sense oligonucleotide 5′-CTGCCAGAAGCCCGCCTACCG-3′, 2 μL of 10 mmol/mL deoxyoligonucleotide triphosphates (Promega), 1 unit Red Hot DNA Polymerase (Abgene), 2 μL of 25 mmol/L MgCl₂, and 4.5 μL of 10× reaction buffer IV (Abgene) were added (in a final volume of 50 μL) and a PCR reaction was performed consisting of 3 min at 95°C and 1 min at 95°C, 1 min at 60°C, and 2 min 72°C for 35 cycles. The product was purified on a Bio-Gel P-6 column (Bio-Rad). DNase I footprint reactions were done with recombinant NF-Y protein in a 50 μL reaction in the same buffer as used for EMSA. After preincubation for 30 min at 4°C, ~0.1 ng radiolabeled probe was added and the mixture was incubated at room temperature for another 30 min. Subsequently, 1 unit RQ1 DNase I (Promega) and the solution was made up to 5 mmol/L MgCl₂ and CaCl₂. Following exactly 3 min of digestion at room temperature, 1 volume stop mix containing 30 mmol/L K-EDTA (pH 8.0), 200 mmol/L NaCl, and 1% SDS was added and samples were purified by phenol-chloroform treatment and alcohol precipitation. The resulting pellets were dried and resuspended in loading buffer [95% formamide, 20 mmol/L K-EDTA (pH 8.0), 0.05% bromophenol blue, and 0.05% xylene cyanol]. The sample was heat denatured for 3 min at 95°C and separated on a 6% denaturing polyacrylamide gel (Sequagel; National Diagnostics). The dried gels were exposed to Kodak X-Omat-LS film with intensifying screens at -80°C.

**Flow Cytometry**

Cells were collected for flow cytometric analysis using trypsin. Cells were fixed using a mixture of 70% ethanol (7 mL) and PBS-0.02% sodium azide (1 mL) and analyzed within 1 week of fixation. Cell pellets were washed with PBS-0.02% sodium azide before being resuspended in 50 mL of 1 mg/mL propidium iodide (Sigma), 25 μL of 10 mg/ml RNase A, and 925 μL PBS-0.02% sodium azide. Subsequently cells were gently mixed and incubated at 4°C for 30 min before analyzing using flow cytometry.

**Western Blotting**

For Western blot analysis, 50 μg nuclear extract was denatured by heating for 3 min at 95°C in sample buffer containing 100 mmol/L Tris-HCl (pH 6.8), 4% SDS, 10% 2-mercaptoethanol, 20% glycerol, and 0.02% bromophenol blue. Bio-Rad high-range SDS-PAGE molecular weight standards were used as a reference. Proteins were separated on a 7% SDS-polyacrylamide mini gel (Mini Protein II System; Bio-Rad) and subsequently transferred (Trans Blot Cell; Bio-Rad) to polyvinylidene difluoride membranes (Immobilon-P; Millipore). Western blot analysis was performed with the IFICH8 rabbit polyclonal topo IIα antibody (kindly provided by Dr. I.D. Hickson) at a 1:5000 dilution using ECL Western blot detection kit and subsequent cell was gently mixed and incubated at 4°C for 30 min before analyzing using flow cytometry.

**Reverse Transcription and Real-Time PCR**

Reverse transcription was carried out essentially as described in the Promega Protocols and Applications Guide, 3rd Edition, 1996. Real-time PCR was carried out using the ABI PRISM 7000 Sequence Detection System (Applied Biosystems). Respectively, the forward and reverse topo IIα primers used were 5′-ATTGAAGACGCTGTTTCGTTATGGG-3′ and 5′-GATGGATAAAATTATCAGCAAGCCT-3′. The probe sequence (CAGATCCAGAACAGGTTGACCTCAG-3′) was visualized by exposing the gels to Kodak X-Omat-LS film. cdk2, cyclin B1, and p53 antibodies were all purchased from Abcam and used at dilutions of 1:400, 1:500, and 1:1000, respectively.

**Molecular Cancer Therapeutics 2008;7(6). May 2008**


Downloaded from mct.aacrjournals.org on December 30, 2017. © 2008 American Association for Cancer Research.
mathematical quantification approach described by Pfaffl (16) and ABI User Bulletins 2 and 5 (2001). This is based on the relative expression ratio of the target gene (topo IIα) compared with that of an internal control gene (glyceraldehyde-3-phosphate dehydrogenase). Standard curves were constructed for both internal and reference genes and slopes of these were used to ensure that both primer sets were equally efficient. The threshold cycle values (Ct) and the efficiencies of the reactions were used to compare the relative expression levels of the target gene in various samples. To ease comparison, levels of topo IIα RNA in untreated, exponentially growing cells were set at a value of 1 and all test samples were expressed at values relative to this.

**Chromatin Immunoprecipitation**

Immunoprecipitations were carried out essentially as described (17) with a few modifications. Cells were cultured and treated in 150 mm plates and treated with 1% formaldehde to induce the cross-linking reaction. Treatment with 0.125 mol/L glycine stopped the reaction and cell pellets were stored at -20°C until analysis. For analysis, cells were resuspended in lysis buffer [5 mmol/L PIPES (pH 8.0), 85 mmol/L KCl, 0.5% NP-40, 1× protease inhibitor cocktail (Sigma) containing 0.5 mmol/L phenylmethylsulfonyl fluoride. Subsequently, nuclei extracted using a Dounce homogenizer were resuspended in sonication buffer [50 mmol/L Tris-HCl (pH 8.0), 10 mmol/L EDTA, 0.1% SDS, 0.5% deoxycholic acid, and 1× protease inhibitor cocktail] and sonicated into 500- to 1,500-bp chromatin fragments. The chromatin fragments were stored at -80°C pending further analysis.

**Immunoprecipitation**

Immunoprecipitations were carried out essentially as described (17) with a few modifications. Cells were cultured and treated in 150 mm plates and treated with 1% formaldehde to induce the cross-linking reaction. Treatment with 0.125 mol/L glycine stopped the reaction and cell pellets were stored at -20°C until analysis. For analysis, cells were resuspended in lysis buffer [5 mmol/L PIPES (pH 8.0), 85 mmol/L KCl, 0.5% NP-40, 1× protease inhibitor cocktail (Sigma) containing 0.5 mmol/L phenylmethylsulfonyl fluoride. Subsequently, nuclei extracted using a Dounce homogenizer were resuspended in sonication buffer [50 mmol/L Tris-HCl (pH 8.0), 10 mmol/L EDTA, 0.1% SDS, 0.5% deoxycholic acid, and 1× protease inhibitor cocktail] and sonicated into 500- to 1,500-bp chromatin fragments. The chromatin fragments were stored at -80°C pending further analysis. Protein G (15 μL; Kierkegard Perry Lab) was precleared overnight with 1 μg/μL salmon testis DNA and 1 μg/μL bovine serum albumin in immunoprecipitation buffer [50 mmol/L Tris-HCl (pH 8.0), 10 mmol/L EDTA, 0.1% SDS, 0.5% deoxycholic acid, and 1× protease inhibitor cocktail, 150 mmol/L LiCl]. Chromatin (25–50 μL) was also precleared by incubating for 2 h with 40 μL protein G slurry in immunoprecipitation buffer at 4°C. The precleared chromatin was placed in pre-siliconated 0.5 mL PCR tubes, up to 8 μg antibody was added (200 μL final volume), and the mixture was incubated overnight at 4°C. Subsequently, 110 μL of the salmon testis DNA-saturated and bovine serum albumin-saturated protein G in immunoprecipitation buffer was added to the chromatin-antibody mixture and the samples were further incubated for 2 h at 4°C. The samples were centrifuged at 4,000 rpm for 2 min and the supernatant was stored at -20°C as a source of “input DNA.” The resin was washed initially at 4°C for 30 min using 300 μL immunoprecipitation buffer. Subsequently, nine more washes were carried out by resuspending the resin in 300 μL immunoprecipitation buffer and centrifuging for 2 min at 4,000 rpm. The bound DNA was then eluted from the resin by adding 100 μL elution buffer (1% SDS, 50 mmol/L NaHCO₃, 1.5 ng/μL salmon testis DNA) and incubating for 1 h at 37°C on a shaker. After centrifugation at 14,000 rpm for 2 min, the supernatant and the input DNA were both incubated overnight at 65°C with 10 μg RNase A and 200 mmol/L NaCl to reverse the cross-links. Following this, the DNA was precipitated with 99% ethanol at -20°C. The pellets were collected by centrifugation at 13,000 rpm for 30 min, washed with 70% ethanol, and air-dried. The protein was removed from the DNA by resuspending the pellets in 40 μg protease K, 25 μL proteinase K buffer [1.25% SDS, 50 mmol/L Tris (pH 7.5), 25 mmol/L EDTA], and 100 μL TE (pH 7.5) and incubating at 42°C for 2 h. Digested protein was removed with phenol/chloroform/isoamyl alcohol (25:24:1) and the DNA was precipitated at −20°C overnight with 30 μL of 3 mol/L sodium acetate, 1 μL of 5 mg/mL tRNA, and 750 μL of 99% ethanol. The sample DNA pellets were resuspended in 60 μL sterile water and the input DNA in 200 μL. The DNA was then used for PCR using 2 μL DNA/sample.

**Results**

**GWL-78 Can Inhibit Protein Binding to the Inverted CCAAT Motif**

The structure and chemical properties of GWL-78 have been described (18). DNA footprinting and in vitro transcription stop assay results suggest that it binds preferentially to the consensus motif 5′-XCXWz (z = 3 ± 1, W = A or T, X = any base but preferably a purine) and that robust sequence-selective blockade of transcription occurs at sites corresponding approximately to its DNA footprints. GWL-78 has also been shown to have good cellular/nuclear penetration properties, and a degree of correlation between cytotoxicity and DNA-binding affinity has been observed (18).

We first investigated the effect of GWL-78 on NF-Y binding to an oligonucleotide containing a CCAAT motif immobilized on a 96-well plate. The immobilized oligonucleotides were incubated with GWL-78 with subsequent addition of HT-29 nuclear extracts. Relative DNA-binding activity of NF-Y is shown in Fig. 2A. To monitor the specificity of the interaction, we used competitive DNA. In this positive control, NF-Y binding was reduced by >80% (lane 5), whereas incubation with a nonspecific oligonucleotide had no effect on NF-Y binding (column 6). Following treatment with GWL-78, there was 48% inhibition of the NF-Y activity (column 4) compared with the control sample (column 1). This showed the ability of GWL-78 to inhibit NF-Y binding to the CCAAT motif.

The topo IIα promoter contains five inverted CCAAT motifs that have been shown to be involved in control of transcriptional expression at confluence, p53-induced down-regulation, and response to heat shock–induced up-regulation (19–21). We performed EMSA assays on ICB motifs within the topo IIα promoter. Using radio-labeled probes of ICB1 to ICB4, GWL-78 was able to inhibit binding of NF-Y to the core motif. There were significant differences in the ability of GWL-78 to inhibit binding to the different ICBs. For ICB1, abolition of binding was seen at 1 and 5 μmol/L with ICB2 (Fig. 2) and 10 μmol/L with ICB3 and was not observed at 50 μmol/L with ICB4. A supershift obtained using antibodies to NF-Y-B confirmed the involvement of NF-Y in the complexes binding to ICBs.
The NF-Y transcription factor binds to CCAAT motifs within a wide variety of eukaryotic promoters. To investigate whether GWL-78 could inhibit NF-Y binding, we did EMSA experiments using radiolabeled oligonucleotides containing NF-Y binding sites from several promoters regulated by NF-Y (5). These included mdr1, cdc2/cdk1 (cyclin-dependent kinase), E2F1, and cyclin B1 (Fig. 2). EMSA experiments showed that GWL-78 was able to inhibit protein binding to cognate NF-Y binding sites within these promoters at concentrations varying from 1 to 50 µmol/L. Binding of GWL-78 to the ICB in mdr1 was abolished at 50 µmol/L and in cdc2 at 10 µmol/L. The two CCAAT boxes in cyclin B1 differed significantly with binding being abolished at 50 µmol/L at CCAAT box 1 and at 5 µmol/L at CCAAT box 2. In the case of the E2F1 sequence, binding was abolished at 10 µmol/L. The two CCAAT boxes of cdc25 did not differ with binding being abolished at 50 µmol/L at both ICB1 and ICB2. Supershift experiments using an antibody to NF-Y-B confirmed that the transcription factor NF-Y was involved in binding to these sites as shown in previous studies.

**In vitro Binding of GWL-78 to the Topo IIα Promoter**

To determine the pattern of binding of GWL-78 to specific sequences within the context of the topo IIα promoter, *in vitro* DNase I footprinting was performed. A radiolabeled probe containing the topo IIα promoter was incubated with varying concentrations of GWL-78 (Fig. 3A). There was a detectable footprint over the ICB2 sequence at 2.5 µmol/L. Addition of recombinant NF-Y to DNA following incubation with GWL-78 showed that it was able to inhibit NF-Y binding to sequences within the topo IIα promoter at 2.5 µmol/L (Fig. 3B). The pattern of the footprint over the ICBS was altered with increasing concentration of drug resulting in a pattern similar to that obtained with drug and DNA alone. This pattern was observed whether the radiolabeled probe was incubated with drug followed by recombinant NF-Y or probe incubated with recombinant NF-Y followed by GWL-78. Therefore, GWL-78 is able to both block the interaction of NF-Y and DNA and displace NF-Y from DNA following binding.

**Demonstration of In vivo Effects of GWL-78 by ChIP Assay**

The EMSA experiments demonstrate the ability of GWL-78 to bind to inverted CCAAT sequences *in vitro*, but it was important to determine if these effects could be shown in intact cells. To assess the cellular effects of GWL-78 on the interaction of NF-Y with DNA, ChIP assays were carried out on promoters examined in Fig. 2 with antibody to NF-Y-B of the NF-Y heterotrimer. To investigate whether GWL-78 could inhibit binding of NF-Y to the topo IIα promoter, NIH3T3 cells were treated with increasing doses of GWL-78 (0.1, 0.3, and 1 µmol/L), and extracts were immunoprecipitated with antibodies to NF-Y-B. Binding of NF-Y to the topo IIα promoter was clearly shown by the ChIP assay, and inhibition of NF-Y binding by GWL-78 was observed at the lowest concentration of the drug and essentially complete at 1 µmol/L (Fig. 4). In parallel, we analyzed binding to other promoters whose CCAAT boxes were

within the topo IIα promoter. The addition of GWL-78 following incubation of nuclear extract with radiolabeled probe showed that GWL-78 is able to displace protein bound to DNA.
analyzed in vitro. cdc2 showed a decrease at the lower doses and abolition at 1 mmol/L. E2F1 and mdr1 were affected only at the highest dose, whereas cdc25c showed only modest inhibition of NF-Y binding. As a control, we analyzed the CCAAT box in the NF-Y-A promoter, whose binding to NF-Y was not affected by GWL-78, and the CCAAT-less promoter nucleolin, which does not contain an ICB. Therefore, GWL-78 is able to enter the nucleus and inhibit transcription factor interaction with DNA with a selectivity mirroring the in vitro binding inhibition data. Topo IIα appears to be the most sensitive promoter in this assay.

GWL-78 Induction of Cell Cycle Arrest
Having shown that GWL-78 blocks NF-Y binding in cells, we then investigated the biological effects of cellular exposure. NF-Y has been shown to be a critical effector of cell cycle progression, and transfection of a dominant-negative NF-Y gene blocks mouse fibroblast cells in the

Figure 3. A and B, DNase I footprinting of the topo IIα promoter with GWL-78. Experiments were performed in the presence of GWL-78 alone (A) and in combination with recombinant NF-Y protein (B). A, lane 1, untreated, DNase I–digested probe; lanes 2 to 7, probe incubated with 0.1, 2.5, 5, 7.5, 10, and 12.5 µmol/L GWL-78, respectively, before digestion. B, lane 1, untreated digested probe; lane 2, probe incubated with recombinant NF-Y before digestion; lanes 3 to 8, samples incubated with 0.1, 2.5, 5, 7.5, 10, and 12.5 µmol/L GWL-78 for 24 h before incubation with recombinant NF-Y protein; lane 9, GA lane. Thick vertical lines, ICBs. Examples of GWL-78 preferred binding sites emboldened (18).
S phase of the cell cycle (7). To determine if GWL-78 could inhibit NF-Y function by blocking DNA-protein interactions, the effects of GWL-78 on cell cycle progression were investigated.

NIH3T3 cells were serum starved and treated with 0.4 mmol/L mimosine to induce G1 arrest. Release of cells by addition of fresh medium containing 10% serum resulted in progression through the cell cycle as shown by flow cytometric analysis (Fig. 5). Following incubation with 1 μmol/L GWL-78, there was G1 arrest at 24 h. Lower doses of GWL-78 (0.1 and 0.5 μmol/L) had a minimal effect on cell cycle progression, and cells progressed through the cell cycle in a normal or slightly more rapid manner in NIH3T3 cells. Figure 5 indicates the percentage of cells in each phase of the cell cycle.

Cells were synchronized by serum starvation and mimosine treatment before release in the presence of GWL-78. Mimosine treatment coupled with serum starvation arrested the cells at the G1 phase of the cell cycle and caused the levels of topo IIα protein to fall in NIH3T3 cells (Fig. 6A). Subsequent release from cell cycle arrest caused the levels of topo IIα protein to rise as the cells progressed through the cell cycle. In NIH3T3 cells treated with 0.1 μmol/L GWL-78, levels of protein increased as the cells progressed through the cell cycle. Treatment with 0.5 μmol/L GWL-78 on release from synchronization also resulted in an increase in the levels of topo IIα, although levels did not return to those observed in untreated and exponentially growing cells. In contrast, cells treated with 1 μmol/L GWL-78 did not progress through the cell cycle. Consequently, the levels of topo IIα did not increase in these cells when released from cell cycle arrest.

Levels of cdk2 and cyclin B1 protein were also examined. The levels of both proteins fell on serum starvation and increased in untreated cells on release from synchronization to levels similar to those of normally cycling cells. On

Figure 4. Effects of GWL-78 on promoters using ChIP assay. NIH3T3 cells were treated for 24 h with 1 μmol/L GWL-78 and ChIP with control (Flag) and anti-NF-Y-B antibodies. The results on CCAAT promoters for topo IIα, E2F1, mdr1, cdc25c, NF-Y-A, and nucleolin, are also shown. Analyses were done with semiquantitative PCR and the data were plotted after scanning of several amplifications in the linear range. Enrichments of the treated samples over the control Flag material were shown as percentage of enrichments of untreated controls: 14-fold (topo II α), 7-fold (cdc2), 16-fold (E2F1), 4-fold (mdr1), and 5-fold (cdc25c). Enrichment of NF-Y-A was >10-fold. No enrichment was observed on the CCAAT-less nucleolin.
treatment with both 0.1 and 0.5 \( \mu \text{mol/L} \) GWL-78 cdk2 levels also increased although not to the levels observed in untreated cells. Cyclin B1 only increased when 0.1 \( \mu \text{mol/L} \) GWL-78 treatments were carried out. No increase in either protein was observed at 1 \( \mu \text{mol/L} \) GWL-78 concentration (Fig. 6B).

It was possible that the biological effects of GWL-78 were secondary to induction of p53 and consequent cell cycle arrest rather than being specifically due to the effects of the drug on blockade of protein/DNA interactions. We assessed induction of p53 following incubation of cells with GWL-78. As shown in Fig. 6C, there was no induction of p53 in cells following GWL-78 treatment at a dose that caused cell cycle arrest (1 \( \mu \text{mol/L} \)). In contrast, exposure to both 50 and 100 \( \mu \text{mol/L} \) etoposide resulted in induction of p53. Therefore, it is likely that the biological effects of GWL-78 in these experiments are not due to nonspecific effects through DNA damage—induced induction of p53.

### Discussion

The heterotrimERIC transcription factor NF-Y has been implicated in a variety of cellular processes, including cell cycle progression and differentiation. A study using transfection of a dominant-negative NF-Y expression plasmid showed that NF-Y is essential for cell cycle progression (7). NF-Y has been shown to exert both stimulatory and inhibitory effects on gene expression. For example, we showed the ability of the bis-benzimidazole Hoechst 33342 to block NF-Y binding to the topo II\( \alpha \) promoter and thereby increase cellular expression of topo II\( \alpha \) in confluent cells (4). In confluent cells, NF-Y has an inhibitory effect and abrogation of NF-Y binding to the promoter results in de-repression and thereby increased levels of topo II. In contrast, in cycling cells, topo II\( \alpha \) is critical for cell cycle progression; inhibition of NF-Y results in decreased topo II\( \alpha \) expression. Several other agents have been shown to inhibit NF-Y/DNA interactions, including the minor-groove binder distamycin (22).

Ideally, one could envisage altering gene expression by using sequence-selective DNA-binding agents to interfere with transcription factor-DNA interactions. In this scenario, human genomic DNA would be the intended target and it is unclear whether the DNA-binding drugs described thus far would be sufficiently selective for a specific gene to avoid being quenched by the large mass of genomic DNA. This is exemplified by the example of NF-Y, which has 56,000 potential CCAAT box binding sites on chromosome 21 alone, yet ChIP on chromatin experiments only detected some 1,000 sites in vivo. Some of this selectivity is certainly due to the inaccessibility of large parts of the genome through compaction in heterochromatin. Some could be regulated by local, promoter-specific hindrance or preference for flanking sequences and recruitment by fellow transcription factors could be critical factors.

### Table

| NIH3T3 cells | G1       | S        | G2       | G4
|--------------|----------|----------|----------|----------
| Exponential  | 45.9 +/- 1.6 | 46 +/- 0.6 | 6.1 +/- 2 |       |
| Serum starved| 70.5 +/- 2.7 | 25.7 +/- 0.9 | 2.7 +/- 0.4 |       |
| 0            | 14.4 +/- 1.9 | 47.3 +/- 1.5 | 35.7 +/- 0.8 |       |
| 0.1          | 10.4 +/- 0.9 | 45.5 +/- 2.3 | 38.8 +/- 1.3 |       |
| 1            | 68.7 +/- 1.9 | 25.1 +/- 1.1 | 3.1 +/- 0.8 |       |

---

* Cerbelli et al., submitted for publication.
In this study, we have investigated the ability of the PBD-poly(N-methylpyrrole) conjugate GWL-78 to block NF-Y binding to DNA. We have shown that following exposure of cells to GWL-78, there is inhibition of cell cycle progression. Interestingly, lower doses of GWL-78 appear to induce more rapid traverse through the cell cycle. The mechanism for this differential effect of GWL-78 is unclear. It could be due to the differential effects of GWL-78 on different promoters depending on the concentration of drug.

Our study suggests that the effects of GWL-78 on gene expression are mediated by a transcriptional block following cellular exposure to drug. Interestingly, this does not appear to involve induction of p53. The data from our study, including EMSA and DNase I footprinting assays, suggest that GWL-78 blocks NF-Y interaction with cognate binding sequences within DNA. Additionally, the DNase I footprint analysis shows that GWL-78 is able to displace NF-Y already bound to the promoter. The result of the ChIP assay confirms the inhibitory effects of GWL-78 in cells. Thus, the effects of GWL-78 are comparable with those found in a study where expression of a dominant-negative NF-Y construct blocked cell cycle progression (7). Most importantly, the effects observed in vivo are a good match with inhibition data. In terms of preference for CCAAT boxes, topo IIa > cdc2 > mdr1 = E2F1 > cdc25. Remarkably, the NF-Y-A promoter, which has four CCAAT boxes, is refractory to GWL-78 treatment. This indicates that NF-Y disappearance from promoters is not due to interference with NF-Y-A production and emphasizes the sequence selectivity and promoter preference of the compound. In some of the EMSA studies (e.g., cyclin B1), there was an appearance of increased protein binding at lower drug concentrations, which could suggest conformational changes in DNA resulting in higher-affinity NF-Y binding. Interestingly, the ChIP assay shows increased NF-Y binding to the E2F1 and mdr1 promoters at lower drug concentrations. However, the inhibition of NF-Y binding to the topo IIa promoter is found even at low concentrations of GWL-78. There is no direct correlation between results of EMSA and ChIP assays. In vivo binding shown in the ChIP assay is dependent on several factors not affecting EMSA, including cell line, intracellular transport mechanisms, and presence of motifs modulating NF-Y binding such as SP1-binding sites (23).

These results suggest that GWL-78 may be exerting its biological effects by binding selectively to key DNA sequences, especially those associated with the ICBs, and leading to transcription block. Several potential binding sites, which fit the consensus motif for GWL-78 as reported by Wells et al. (18) (that is, 5’-XGXWz, where z = 3 ± 1, W = A or T, X = any base but preferably a purine), are evident in the DNA sequences relating to ICB1 to ICB3. One binding site example from each ICB is highlighted in bold in the sequence labels of the footprints in Fig. 3, although there are many more.

We recently showed that a polyamide directed against the binding site of NF-Y in the topo IIa promoter was able to inhibit NF-Y binding and alter gene expression in confluent cells (2). Other studies have shown that polyamides can modulate gene expression in vivo (24). An important difference with GWL-78 is the apparent progression of cell cycle found with lower concentrations. NF-Y has been shown to have pleiotropic transcriptional effects on different genes with both activation and repression of promoters. It is possible that GWL-78 may
affect a differing population of promoters binding NF-Y at different concentrations. Given the large number of promoters with consensus NF-Y binding sites, it is likely that it is the pattern of promoter repression that determines the effects of GWL-78 at a given dose. To determine such patterns, we are currently using a ChIP on chip strategy.

In conclusion, by all criteria used here (EMSA, DNase I footprint, ChIP, and expression analysis), the PBD-polyamide conjugate GWL-78 shows the ability to inhibit specific DNA-protein interactions. Its cellular penetration and consequent modulation of gene transcription suggest that such agents can be exploited to target the cellular transcription machinery. The balance between the cytotoxicity caused by agents of this type and their transcriptional effects will be a critical factor in their therapeutic application and will be the subject of future investigation.

Disclosure of Potential Conflicts of Interest

P.W. Howard, D.E. Thurston, and J.A. Hartley: equity interest in Spirogen Ltd., owner of GWL-78; D. Hochhauser: consultancy fees from Spirogen Ltd. The other authors reported no potential conflicts of interest.

References

6. Ronchi A, Bellorini M, Mongelli N, Mantovani R. CCAAT-box binding proteins with consensus NF-Y binding sites, it is likely that it is the pattern of promoter repression that determines the effects of GWL-78 at a given dose. To determine such patterns, we are currently using a ChIP on chip strategy.

In conclusion, by all criteria used here (EMSA, DNase I footprint, ChIP, and expression analysis), the PBD-polyamide conjugate GWL-78 shows the ability to inhibit specific DNA-protein interactions. Its cellular penetration and consequent modulation of gene transcription suggest that such agents can be exploited to target the cellular transcription machinery. The balance between the cytotoxicity caused by agents of this type and their transcriptional effects will be a critical factor in their therapeutic application and will be the subject of future investigation.

Disclosure of Potential Conflicts of Interest

P.W. Howard, D.E. Thurston, and J.A. Hartley: equity interest in Spirogen Ltd., owner of GWL-78; D. Hochhauser: consultancy fees from Spirogen Ltd. The other authors reported no potential conflicts of interest.

References

6. Ronchi A, Bellorini M, Mongelli N, Mantovani R. CCAAT-box binding proteins with consensus NF-Y binding sites, it is likely that it is the pattern of promoter repression that determines the effects of GWL-78 at a given dose. To determine such patterns, we are currently using a ChIP on chip strategy.

In conclusion, by all criteria used here (EMSA, DNase I footprint, ChIP, and expression analysis), the PBD-polyamide conjugate GWL-78 shows the ability to inhibit specific DNA-protein interactions. Its cellular penetration and consequent modulation of gene transcription suggest that such agents can be exploited to target the cellular transcription machinery. The balance between the cytotoxicity caused by agents of this type and their transcriptional effects will be a critical factor in their therapeutic application and will be the subject of future investigation.
Molecular Cancer Therapeutics

Inhibition of DNA binding of the NF-Y transcription factor by the pyrrolobenzodiazepine-polyamide conjugate GWL-78

Minal Kotecha, Jerome Kluza, Geoff Wells, et al.

Mol Cancer Ther 2008;7:1319-1328.

Updated version
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/7/5/1319

Cited articles
This article cites 22 articles, 12 of which you can access for free at:
http://mct.aacrjournals.org/content/7/5/1319.full#ref-list-1

Citing articles
This article has been cited by 3 HighWire-hosted articles. Access the articles at:
http://mct.aacrjournals.org/content/7/5/1319.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://mct.aacrjournals.org/content/7/5/1319. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.